The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Eva Mikaelsson(Karolinska University Hospital), Abdul Salam Khan(Karolinska University Hospital), Amir Hossein Daneshmanesh(Karolinska University Hospital), Ali Moshfegh(Karolinska University Hospital)
Cited by 99
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312